Janssen 64042056ALZ2001

Back to Drug Development Trials
Drug Development Trials

About the trial

A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Safety and Tolerability, Effect on tau Pathology and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer’s Disease.